Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1497
Peer-review started: April 8, 2023
First decision: May 27, 2023
Revised: June 7, 2023
Accepted: July 18, 2023
Article in press: July 18, 2023
Published online: August 15, 2023
Processing time: 123 Days and 21 Hours
The molecular changes present in gastric neuroendocrine tumors (NETs) include a loss of heterozygosity or mutation of MEN1, CDKN1B gene mutation, P27 heterozygous mutation, and ATP4A gene missense mutation. We identified and are the first to report a case of type 1 histamine-producing enterochromaffin-like cell NETs (ECL-cell NETs) with a BRCA2 gene germline mutation.
The patient had a history of iron-deficient anemia for 5 years, and gastroscopic examination indicated multiple gastric tumors. Then, the patient underwent distal gastrectomy. Microscopically, multifocal tumor cells were found in the mucosa and submucosa; tumor cells were organoid and arranged in nests and cords, and the stroma was rich in sinusoids. The surrounding gastric mucosa showed atrophy with mild intestinal metaplasia or pseudopyloric gland metaplasia. Neuroendocrine cells could be seen with diffuse linear, nodular, and adeno
This is the first report of a case of type 1 gastric ECL-cell NETs with a pathogenic germline mutation of the BRCA2 gene. The findings of this report will expand the germline mutation spectrum of gastric NETs and increase the understanding of the molecular changes present in these tumors for their improved diagnosis in the future.
Core Tip: Type 1 enterochromaffin-like neuroendocrine tumors (ECL-cell NETs) occur most frequently and are associated with autoimmune gastritis. In gastric neuroendocrine tumors, molecular changes occur in genes including MEN1, CDKN1B, P27, and ATP4A. This is the first report of type 1 ECL-cell NETs with a pathogenic germline mutation of the BRCA2 gene.
